Clinical Trial Update: Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma [Phase 1]

View source ↗

Summary

Phase I study of 131-I mIBG followed by nivolumab and dinutuximab beta for children with relapsed/refractory neuroblastoma is listed as active non-recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• 131-I mIBG (Iodine-131 metaiodobenzylguanidine)
• dinutuximab beta (dinutuximab beta)
• nivolumab (nivolumab)

Snippet

Sponsor: University Hospital Southampton NHS Foundation Trust | Conditions: Neuroblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING